X

Month: November 2022

2022 11 24

Scandinavian Biopharma

Scandinavian Biopharma welcomes Johan Jarmander to the position as Drug Substance Specialist Manufacturing & Development

Scandinavian Biopharma continues to strengthen its organization in manufacturing and is pleased to welcome Johan Jarmander as our new Drug Substance Specialist Manufacturing & Development. Johan holds a doctorate degree in biotechnology from the KTH Royal Institute of Technology and has extensive experience from manufacturing of biological medicinal products. Johan comes most recently from Octapharma […]

2022 11 16

Distribution

Scandinavian Biopharma

Scandinavian Biopharma enters into a commercial collaboration with Novavax in Sweden

Scandinavian Biopharma and Novavax have signed a commercial collaboration agreement for the Covid vaccine Nuvaxovid. Nuvaxovid is an adjuvanted protein-based vaccine that protects against SARS Covid-19. Scandinavian Biopharma has extensive experience in the sale and marketing of vaccines. As of October 2022, the company is the representative for Nuvaxovid on the Swedish market and will […]

2022 11 14

R&D

Scandinavian Biopharma

Scandinavian Biopharma has successfully completed the enrolment of their large Phase IIb trial in The Gambia

We are proud to announce that all participants have received the third and final vaccination dose in our large randomized, placebo-controlled, and double-blind phase IIb study in The Gambia. The study started in 2021 and is part of the late phase development program in Africa for Scandinavian Biopharma’s vaccine candidate, ETVAX®, against Enterotoxigenic Escherichia coli […]

2022 11 08

Scandinavian Biopharma

We continue to expand and welcome Marja Held as Senior Regulatory Affairs Manager

Scandinavian Biopharma continue to strengthen the organization in regulatory affairs through the recruitment of Marja Held as the new Senior Regulatory Affairs Manager. Marja has Master of Science in Pharmacy from Uppsala University, and she has an extensive experience in Regulatory Affairs from various pharmaceutical companies both small-size and larger enterprises. She most recently came […]